recombinant human transforming growth factor type β3 tgfβ3 Search Results


growth factor beta 3  (R&D Systems)
95
R&D Systems growth factor beta 3
Growth Factor Beta 3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pmc12288050-97-63-68?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
growth factor beta 3 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
tgfβ3  (R&D Systems)
95
R&D Systems tgfβ3
Tgfβ3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pm40074890-573-25-29?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
tgfβ3 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
human tgfβ3  (R&D Systems)
94
R&D Systems human tgfβ3
Human Tgfβ3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pmc04035041-136-17-19?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human tgfβ3 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
mouse monoclonal antibody to tgfβ3  (R&D Systems)
92
R&D Systems mouse monoclonal antibody to tgfβ3
Figure 1. Effects of asoprisnil on the expression of immunoreactive epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) and transforming growth factor β <t>(TGFβ3)</t> protein in leiomyoma and normal myometrial cells cultured for 48 or 72 h, as assessed by immunocyto- chemistry. The expression of immunoreactive EGF, IGF-I and TGFβ3 protein in leiomyoma and normal myometrial cells cultured for 48 h (upper panel) and for 72 h (lower panel). EGF in leiomyoma cells cultured without any treatment (a, A), EGF in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (d, D), IGF-I in leiomyoma cells cultured without any treatment (b, B), IGF-I in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (e, E), TGFβ3 in leiomyoma cells cultured without any treatment (c, C) and TGFβ3 in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (f, F). EGF in normal myometrial cells cultured without any treatment (g, G), EGF in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (j, J), IGF-I in normal myometrial cells cultured without any treatment (h, H), IGF-I in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (k, K), TGFβ3 in normal myometrial cells cultured without any treatment (i, I) and TGFβ3 in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (l, L). Bars represent 50 μm. Original magnification 40.
Mouse Monoclonal Antibody To Tgfβ3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pm16613890-61-22-28?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
mouse monoclonal antibody to tgfβ3 - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
anti tgfβ3  (R&D Systems)
90
R&D Systems anti tgfβ3
Figure 1. Effects of asoprisnil on the expression of immunoreactive epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) and transforming growth factor β <t>(TGFβ3)</t> protein in leiomyoma and normal myometrial cells cultured for 48 or 72 h, as assessed by immunocyto- chemistry. The expression of immunoreactive EGF, IGF-I and TGFβ3 protein in leiomyoma and normal myometrial cells cultured for 48 h (upper panel) and for 72 h (lower panel). EGF in leiomyoma cells cultured without any treatment (a, A), EGF in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (d, D), IGF-I in leiomyoma cells cultured without any treatment (b, B), IGF-I in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (e, E), TGFβ3 in leiomyoma cells cultured without any treatment (c, C) and TGFβ3 in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (f, F). EGF in normal myometrial cells cultured without any treatment (g, G), EGF in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (j, J), IGF-I in normal myometrial cells cultured without any treatment (h, H), IGF-I in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (k, K), TGFβ3 in normal myometrial cells cultured without any treatment (i, I) and TGFβ3 in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (l, L). Bars represent 50 μm. Original magnification 40.
Anti Tgfβ3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pmc04608261-354-29-30?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
anti tgfβ3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
recombinant human tgfβ3  (OSI Pharmaceuticals)
90
OSI Pharmaceuticals recombinant human tgfβ3
Figure 1. Effects of asoprisnil on the expression of immunoreactive epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) and transforming growth factor β <t>(TGFβ3)</t> protein in leiomyoma and normal myometrial cells cultured for 48 or 72 h, as assessed by immunocyto- chemistry. The expression of immunoreactive EGF, IGF-I and TGFβ3 protein in leiomyoma and normal myometrial cells cultured for 48 h (upper panel) and for 72 h (lower panel). EGF in leiomyoma cells cultured without any treatment (a, A), EGF in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (d, D), IGF-I in leiomyoma cells cultured without any treatment (b, B), IGF-I in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (e, E), TGFβ3 in leiomyoma cells cultured without any treatment (c, C) and TGFβ3 in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (f, F). EGF in normal myometrial cells cultured without any treatment (g, G), EGF in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (j, J), IGF-I in normal myometrial cells cultured without any treatment (h, H), IGF-I in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (k, K), TGFβ3 in normal myometrial cells cultured without any treatment (i, I) and TGFβ3 in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (l, L). Bars represent 50 μm. Original magnification 40.
Recombinant Human Tgfβ3, supplied by OSI Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+transforming+growth+factor+type+%CE%B23+tgf%CE%B23/pmc05814809-44-0-10?v=OSI+Pharmaceuticals
Average 90 stars, based on 1 article reviews
recombinant human tgfβ3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Effects of asoprisnil on the expression of immunoreactive epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) and transforming growth factor β (TGFβ3) protein in leiomyoma and normal myometrial cells cultured for 48 or 72 h, as assessed by immunocyto- chemistry. The expression of immunoreactive EGF, IGF-I and TGFβ3 protein in leiomyoma and normal myometrial cells cultured for 48 h (upper panel) and for 72 h (lower panel). EGF in leiomyoma cells cultured without any treatment (a, A), EGF in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (d, D), IGF-I in leiomyoma cells cultured without any treatment (b, B), IGF-I in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (e, E), TGFβ3 in leiomyoma cells cultured without any treatment (c, C) and TGFβ3 in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (f, F). EGF in normal myometrial cells cultured without any treatment (g, G), EGF in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (j, J), IGF-I in normal myometrial cells cultured without any treatment (h, H), IGF-I in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (k, K), TGFβ3 in normal myometrial cells cultured without any treatment (i, I) and TGFβ3 in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (l, L). Bars represent 50 μm. Original magnification 40.

Journal: Human reproduction (Oxford, England)

Article Title: A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.

doi: 10.1093/humrep/del035

Figure Lengend Snippet: Figure 1. Effects of asoprisnil on the expression of immunoreactive epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) and transforming growth factor β (TGFβ3) protein in leiomyoma and normal myometrial cells cultured for 48 or 72 h, as assessed by immunocyto- chemistry. The expression of immunoreactive EGF, IGF-I and TGFβ3 protein in leiomyoma and normal myometrial cells cultured for 48 h (upper panel) and for 72 h (lower panel). EGF in leiomyoma cells cultured without any treatment (a, A), EGF in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (d, D), IGF-I in leiomyoma cells cultured without any treatment (b, B), IGF-I in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (e, E), TGFβ3 in leiomyoma cells cultured without any treatment (c, C) and TGFβ3 in leiomyoma cells cultured in the presence of 10–7 M asoprisnil (f, F). EGF in normal myometrial cells cultured without any treatment (g, G), EGF in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (j, J), IGF-I in normal myometrial cells cultured without any treatment (h, H), IGF-I in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (k, K), TGFβ3 in normal myometrial cells cultured without any treatment (i, I) and TGFβ3 in normal myometrial cells cultured in the presence of 10–7 M asoprisnil (l, L). Bars represent 50 μm. Original magnification 40.

Article Snippet: A mouse monoclonal antibody to human EGF (MAB236, R&D Systems), a goat polyclonal antibody to human IGF-I (AF-291-NA, R&D Systems) and a mouse monoclonal antibody to TGFβ3 (MAB643, R&D Systems) were used as the primary antibodies at a dilution of 1:20, 1:50 and 1:50, respectively.

Techniques: Expressing, Cell Culture

Figure 4. Effects of asoprisnil on the number of viable leiomyoma and normal myometrial cells cultured for 72 h in the presence of either recombinant epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) or transforming growth factor β (TGFβ3), as assessed by 3-(4,5-dimethylthi- azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Treatment with 100 ng/ml recombinant EGF signifi- cantly increased the number of viable cultured leiomyoma cells compared with untreated control cultures, and the concomitant treatment with 10–

Journal: Human reproduction (Oxford, England)

Article Title: A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.

doi: 10.1093/humrep/del035

Figure Lengend Snippet: Figure 4. Effects of asoprisnil on the number of viable leiomyoma and normal myometrial cells cultured for 72 h in the presence of either recombinant epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I) or transforming growth factor β (TGFβ3), as assessed by 3-(4,5-dimethylthi- azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Treatment with 100 ng/ml recombinant EGF signifi- cantly increased the number of viable cultured leiomyoma cells compared with untreated control cultures, and the concomitant treatment with 10–

Article Snippet: A mouse monoclonal antibody to human EGF (MAB236, R&D Systems), a goat polyclonal antibody to human IGF-I (AF-291-NA, R&D Systems) and a mouse monoclonal antibody to TGFβ3 (MAB643, R&D Systems) were used as the primary antibodies at a dilution of 1:20, 1:50 and 1:50, respectively.

Techniques: Cell Culture, Recombinant, MTS Assay, Control